Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 08/29 10:00:00 pm
78.17 USD   -2.01%
08/29 NASDAQ 100 MOVE : Gild, tmus
08/27 GILEAD SCIENCES : Alliancebernstein buys $1,063,199,237 stake in Gil..
08/27 GILEAD SCIENCES : Canada Pension Plan Investment Board buys $506,849..
News SummaryMost relevantAll newsSector news 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
08/29 NASDAQ 100 MOVERS : Gild, tmus
08/27 GILEAD SCIENCES : Alliancebernstein buys $1,063,199,237 stake in Gilead Sciences..
08/27 GILEAD SCIENCES : Canada Pension Plan Investment Board buys $506,849,018 stake i..
08/23 GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
08/23 GILEAD SCIENCES : Kelly A. Kramer Joins Gilead Sciences’ Board of Director..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead&..
08/13 EXPRESS SCRIPTS : A secretive board controls access to prescription drugs for mi..
08/12 GENMAB A/S : Enters Commercial License Agreement with Gilead for DuoBody Technol..
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/29 My Updated Portfolio, With 2 Purchases
08/29 GILEAD : Forbes Is Salty Over The Vermont Initiative
08/29 GILEAD SCIENCES : Stay Focused On Yields
08/29 GILEAD : A Threat Overlooked
08/26 CyberArk Software Still Has Hope - Cramer's Lightning Round (8/25/16)
Financials ($)
Sales 2016 30 499 M
EBIT 2016 20 177 M
Net income 2016 14 534 M
Debt 2016 5 857 M
Yield 2016 2,37%
P/E ratio 2016 7,35
P/E ratio 2017 6,97
EV / Sales 2016 3,57x
EV / Sales 2017 3,46x
Capitalization 103 158 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 107 $
Spread / Average Target 37%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-22.75%103 158
AMGEN, INC.5.66%128 351
ACTELION LTD17.62%18 227
More Results